5-Lipoxygenase expression in benign and malignant canine prostate tissues

• Published in: Veterinary & comparative oncology 2011-06, Vol.9 (2), p.149-157
• Main Authors: Goodman, L.A, Jarrett, C.L, Krunkosky, T.M, Budsberg, S.C, Northrup, N.C, Saba, C.F, LeRoy, B.E
• Format: Article
• Language: English
• Subjects: Animals; apoptosis; Arachidonate 5-Lipoxygenase - metabolism; Blotting, Western - veterinary; carcinoma; dog; Dog Diseases - enzymology; Dog Diseases - pathology; Dogs; gene expression regulation; humans; hyperplasia; immunohistochemistry; Immunohistochemistry - veterinary; leukotriene; Male; metastasis; Neoplasm Metastasis; pathogenesis; phenotype; Prostatic Hyperplasia - enzymology; Prostatic Hyperplasia - veterinary; prostatic neoplasms; Prostatic Neoplasms - enzymology; Prostatic Neoplasms - pathology; Prostatic Neoplasms - veterinary; prostatitis
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/j.1476-5829.2010.00245.x

5-Lipoxygenase (5-LO) is overexpressed in human prostate carcinomas (PCs), and its inhibition decreases proliferation and induces apoptosis in prostate cancer cell lines. We hypothesized that 5-LO would be overexpressed in canine PC compared with benign prostate tissue and may be important in the pathogenesis of the disease. Immunoblot analysis of canine PC and benign prostatic hyperplasia (BPH) tissues demonstrated 5-LO expression in both. 5-LO immunohistochemical staining was not significantly different within the stromal or epithelial components of canine primary PC, BPH or suppurative prostatitis, suggesting that differential expression of this enzyme does not occur in these conditions. The percentage of tumour cells expressing 5-LO was significantly lower in metastatic PC lesions compared with primary PC (P < 0.0001). This decreased expression may indicate down-regulation or altered expression of the enzyme with progression of canine PC to a metastatic phenotype.